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Class I major histocompatibility complex (MHC) mol-
ecules bind short peptides derived from proteins syn-
thesized within the cell. These complexes of peptide and
class I MHC (pMHC) are transported from the endoplas-
mic reticulum to the cell surface. If a clonotypic T cell
receptor expressed on a circulating T cell binds to the
pMHC complex, the cell presenting the pMHC is killed.
In this manner, some tumor cells expressing aberrant
proteins are recognized and removed by the immune
system. However, not all tumors are recognized effi-
ciently. One reason hypothesized for poor T cell recog-
nition of tumor-associated peptides is poor binding of
those peptides to class I MHC molecules. Many peptides,
derived from the proto-oncogene HER-2/neu have been
shown to be recognized by cytotoxic T cells derived from
HLA-A21 patients with breast cancer and other adeno-
carcinomas. Seven of these peptides were found to bind
with intermediate to poor affinity. In particular, GP2
(HER-2/neu residues 654–662) binds very poorly even
though it is predicted to bind well based upon the pres-
ence of the correct HLA-A2.1 peptide-binding motif. Al-
tering the anchor residues to those most favored by
HLA-A2.1 did not significantly improve binding affinity.
The crystallographic structure shows that unlike other
class I-peptide structures, the center of the peptide does
not assume one specific conformation and does not
make stabilizing contacts with the peptide-binding cleft.
Class I major histocompatibility complex (MHC)1 proteins
bind short peptides (9–11 amino acids) derived from cytosoli-
cally degraded proteins. These peptides are transported into
the endoplasmic reticulum and bind to newly formed class I
molecules. Peptide binding appears to be the final step in
assembly of the complex (1). Following peptide binding, the
complexes are transported to the plasma membrane. At the
plasma membrane, clonotypic T cell receptors on the surface of
circulating cytotoxic T lymphocytes (CTL) may recognize the
peptide-MHC complex (pMHC). If the pMHC is recognized by
the T cell receptor, the T cell is activated and the cell present-
ing the pMHC is killed. A normal cell will have a large assort-
ment of pMHC on the cell surface that are not recognized by
CTL. However, viral or mutated self-proteins are degraded by
these same mechanisms, and many of the resulting pMHC are
recognized by CTL. In this manner, virus-infected or mutated
cells are targeted for lysis by cytotoxic T cells (reviewed in Ref.
2). Self-proteins that are expressed in abnormally high
amounts or in abnormal cell types may also be targets for CTL
(3).
Class I MHC molecules bind many peptides with diverse
sequences and high affinity (4). To bind all these peptides, the
class I protein primarily interacts with the invariant portions
of the peptides, the N and C termini (5). Class I MHC also uses
a subset of amino acid side chains within the peptide termed
“anchors” to generate significant binding (6). These peptide
anchor residues bind within “specificity pockets” that are pri-
marily formed by the polymorphic residues within the peptide-
binding cleft of the MHC molecule (7). Peptides that bind with
high affinity to a given allotype are typically found to have one
of a few preferred amino acids at each anchor position. The
corresponding hypothesis is that peptides that do not have
those preferred amino acids at the anchor positions will not
bind well. The combination of amino acids that may bind at the
anchor positions is known as the peptide-binding motif (8).
These motifs have proven to be extremely valuable in predict-
ing peptides that will bind to class I MHC. Other residues
within the peptide besides the anchors may be used to generate
increased binding affinity (9–11).
Interestingly, many peptides that appear to have the correct
peptide-binding motif still bind poorly. Substituting the anchor
residues of poor binding peptides with those that are most
preferred by the allotype can generate high affinity binding.
(10, 12). Some of these altered peptide ligands (APL) are even
effective therapeutics (13). We show here that there are also
peptides for which altering the anchor residues does not sig-
nificantly increase binding affinity. It is not clear from the
previously available data in the literature why these peptides
bind poorly.
HER-2/neu (c-erb-2) encodes a receptor tyrosine kinase with
homology to the epidermal growth factor receptor. Overexpres-
sion of HER-2/neu in many adenocarcinomas, including breast
and ovarian tumors, correlates with a poor prognosis for remis-
sion and recovery (14). Tumor infiltrating lymphocytes have
been found in cancer patients that overexpress HER-2/neu, and
these tumor infiltrating lymphocytes are able to recognize and
lyse the solid tumor (3, 15, 16), but these CTL do not eliminate
the tumor. It has also been shown that several peptide epitopes
derived from the gene product of HER-2/neu are presented by
class I MHC molecules to circulating CTL. As with many other
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tumor-associated antigens, most of these peptides bind poorly
to HLA-A2.1 (A2). There are many potential reasons for the
lack of immune removal of tumors including the down-regula-
tion of class I MHC or down-regulation of the protein from
which the peptide is derived. It has also been proposed that one
reason for poor recognition by CTL is weak binding of the
immunogenic peptides to class I MHC (3).
Here we show that HER-2/neu-derived peptides, identified in
the literature as recognized by CTL, bind with a range of
affinities, but all are lower affinity than two index peptides of
high affinity. One peptide was chosen for further study. This
peptide, GP2 (IISAVVGIL), binds very poorly to A2 but has
anchor residues that are present in high affinity peptides (Ile at
position 2 and Leu at position 9). Its inherently poor affinity is
not significantly increased by substitution of its anchor resi-
dues. To understand why this peptide binds poorly, the crys-
tallographic structure of the A2-GP2 complex was determined.
Unlike all previously determined peptide-class I MHC (pMHC)
structures, there is a large region of unresolved electron den-
sity in the center of the peptide. We interpret this to mean that
the peptide assumes more than one conformation within the
peptide-binding cleft. We hypothesize that the observed poor
binding is due to the lack of important secondary interactions
within the center of the peptide.
EXPERIMENTAL PROCEDURES
Preparation of HLA-A2.1-Peptide Complexes—Residues 1–275 of
HLA-A2.1 (A2) and residues 1–99 of human b2-microglobulin were
expressed in Escherichia coli, produced as inclusion bodies, purified,
and folded as described previously (17). Briefly, peptide, solubilized
b2-microglobulin and solubilized A2 heavy chain were rapidly diluted
into folding buffer (10 mM Tris, pH 8.0, 0.4 M L-Arg, 10 mM reduced
glutathione, 1 mM oxidized glutathione, and protease inhibitors) at
molar ratios of 10:5:1, respectively. The final protein concentration was
kept below 50 mg ml21. The solution was incubated at 10 °C for 36–48
h and then concentrated (Amicon) and purified by HPLC gel filtration
(Phenomenex, BioSep-SEC-S2000).
Synthetic Peptides—All peptides were synthesized by the Peptide
Synthesis Facility at the University of North Carolina at Chapel Hill.
The peptides were purified to greater than 95% purity by reversed-
phase HPLC and identity confirmed by matrix-assisted laser desorption
ionization-time-of-flight spectroscopy. Peptides were dissolved in 100%
dimethyl sulfoxide at 20 mg ml21 by weight. The final peptide concen-
tration was determined by amino acid analysis (Protein Chemistry
Laboratory, Department of Chemistry, University of North Carolina,
Chapel Hill). The list of peptides and references for immunogenicity are
given in Table I.
Determination of Thermal Stability—Purified A2-peptide complexes
were exchanged into a 10 mM KH2/K2HPO4 buffer, pH 7.5, and adjusted
to a final protein concentration of 4–12 mM. The change in CD signal at
218 nm was measured as a function of temperature from 4 to 95 °C on
an AVIV 62-DS spectropolarimeter (Aviv Associates Inc, Lakewood,
NJ). The final melting curve was the average of at least three experi-
ments for each A2-peptide complex. Tm values were calculated as the
temperature at which 50% of the complexes are denatured using a
two-state denaturation model (12).
Cell Surface Stabilization Assay—Cell surface stabilization of A2
was performed as described previously (11). Briefly, 2.5 3 105 T2 cells
(ATCC CRL-1992) were incubated overnight in AIM V serum-free me-
dium (Life Technologies, Inc.) at 37 °C, 5% CO2 in the presence of GP2
or APL, at concentrations varying from 50 to 0.05 mM. Cells were then
stained with the monoclonal antibody BB7.2 (18) specific for A2, fol-
lowed by fluorescein isothiocyanate-labeled (1:50) goat anti-mouse IgG
antibody (Southern Biotechnology Associates). Cells were analyzed by
flow cytometry (FACScan, Becton Dickinson), and the mean channel
fluorescence was determined using the CYCLOPS software package
(Cytomation, Fort Collins, CO). All data are normalized as the percent-
age of the mean channel fluorescence for the calreticulin-signal-se-
quence peptide, ML, bound to A2 at 50 mM. Binding by the A2-specific
antibody, BB7.2, was not dependent on the peptide bound because
W6/32, an antibody that binds to an epitope between the a3 domain and
b2-microglobulin, gave similar results (data not shown).
Cell Surface Half-life Assay—The determination of cell surface half-
lives (T1⁄2) of A2-peptide complexes was performed as described previ-
ously (11). Briefly, 2.5 3 106 T2 cells were incubated overnight in AIM
V serum-free medium at 37 °C, 5% CO2 in the presence of 50 mM
peptide. To block the egress of new A2 molecules to the surface, cells
were incubated at 37 °C, 5% CO2 in RPMI 1640, 15% fetal calf serum
and 10 mg ml21 brefeldin A (BFA, Sigma). This concentration of BFA is
toxic to the cells. Therefore, after 1 h the cells were then transferred to
RPMI 1640, 15% fetal calf serum, and 0.5 mg ml21 BFA. At the indicated
time points, 2.5 3 105 cells were removed, incubated with BB7.2, and
analyzed by flow cytometry as described above for cell surface stabili-
zation assay. Each time point is evaluated as mean fluorescence with
peptide minus mean fluorescence without peptide and normalized to
the maximal level of fluorescence (at time zero) for each peptide.
Crystallization, Data Collection and Processing—Crystals were
grown by hanging drop vapor diffusion as described previously (19).
Crystallographic data of A2-GP2 were collected on a single crystal at
the National Synchrotron Light Source, Brookhaven National Labs,
beamline X-12B at 2170 °C (Oxford Cryosystems). Evaluation of the
diffraction pattern with DENZO autoindexing function showed the
space group to be triclinic P1. 180 degrees of data were collected at a
distance of 90 mm from the Quantum 4 CCD detector (ADSC Poway,
CA) with one-degree oscillations and 3 min of exposure time/frame.
Data were processed with DENZO, and intensities were scaled with
SCALEPACK (20). Data statistics are shown in Table II.
Structure Determination and Refinement—The A2-GP2 structure
was determined by molecular replacement using AMoRe (21) within the
CCP4 program suite (22). The A2-hepatitis peptide complex (PDB ac-
cession code 1HHH) was used as the search model (23). Because the
domains tend to vary in their relative orientations with respect to one
another in different crystal forms, the search model was divided into
three pieces, the peptide-binding superdomain (a1a2), the a3 domain,
and b2-microglobulin. Initial rounds of positional refinement used X-
PLOR from 8–2.4 Å resolution data. Later rounds were performed with
Refmac using all data from 30.0 to 2.4 Å. Final rounds of refinement
used torsional dynamics with CNS (24–26) with all data. Electron
density maps were generated using DM and functions for 2-fold non-
crystallographic averaging, histogram matching, and solvent flatten-
ing. Manual intervention was performed using O (27). 103 water mol-
ecules were added to the structure using the program ARP (28)
combined with Refmac and confirmed by visual inspection of the elec-
tron density maps. The refinement statistics are listed in Table II.
RESULTS
HER-2/neu-derived Peptides Bind Poorly to A2—We began
these studies to assess the correlation of immunological activ-
ity with peptide binding affinity to HLA-A2.1 (A2). Thermal
stability of class I MHC-peptide complexes, as measured by
TABLE I
Summary of binding data of HER-2/neu-derived peptides to A2
Residues substituted with respect to wild-type peptide are shown in
boldface type. Tm is the temperature (°C) at which 50% of the protein is
denatured as measured by circular dichroism. Kr is the relative binding
constant as determined by the T2 cell surface assembly assay. Kr is
defined as the concentration of peptide in mM that yields 50% mean
channel fluorescence as compared to the maximum fluorescence of the
control peptide (ML) at 50 mM. The Kr value for ML is the concentration
that yields 50% mean channel fluorescence. T1/2 is the half-life of
peptide-A2 complexes (in hours) as determined by the T2 cell surface
stability assay. ND, not determined. DNF, did not fold in vitro. The
error in the Tm is the sum of the machine and curve fit errors. It is
typically about 1 °C. .50 means that the concentration to yield 50% of
ML fluorescence is greater than 50 mM.
Peptide Sequence Tm Kr T1/2
GP2 (16) IISAVVGIL 36.4 .50 0.35
S1 (38) SIISAVVGI 44.2 13.2 4.05
L10 (38) IISAVVGILL 41.3 .50 1.58
E74 (15) DVRLVHRDL DNF .50 DNB
E75 (15) KIFGSLAFL 45.1 14.4 8.57
F56 (39) YISAWPDSL 34.8 .50 DNB
C84 (39) ELVSEFSRV 37.5 .50 0.30
L9V IISAVVGIV 38.8 .50 0.69
I2L ILSAVVGIL 42.2 22.9 1.76
I2L/L9V ILSAVVGIV 42.5 10.0 2.48
ML (30) MLLSVPLLL 52.5 1.8 19.53
RT (31) ILKEPVHGV 50.0 7.7 9.69
MelA (36) EAAGIGILTV 40.9 47.2 0.44
MelA-A2L ELAGIGILTV 50.0 1.6 9.98
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circular dichroism, have been shown to correlate with the free
energy of peptide binding to class I MHC (29). Therefore, the
thermal stabilities of recombinant A2 complexes folded in vitro
with seven HER-2/neu peptides identified as important
epitopes for breast cancer immunotherapy in the literature
(GP2, S1, L10, E74, E75, F56, and C84; see Table I for se-
quences) were determined. As can be seen from Fig. 1A, com-
plexes formed with GP2, F56, and C84 have extremely low
melting temperatures. Complexes formed with S1, L10, and
E75 (summarized in Table I) have higher melting tempera-
tures. E74 bound so poorly as to be undetectable in any of our
assays (data not shown). A cell surface binding assay (Fig. 1B)
using T2 cells with exogenously added peptide confirms the
results found by the circular dichroism experiments. Two pep-
tides, one hydrophobic and one hydrophilic, were chosen as
representative “high affinity” binders. ML is derived from the
signal sequence of calreticulin (30), and RT is derived from HIV-1
reverse transcriptase (31). The thermal stability (Tm) and the
relative binding constant (Kr) determined by the T2 assay corre-
late well (91.3% correlation coefficient). This suggests that Kr is
proportional to KD, because, as stated above, the Tm has previ-
ously been shown to be proportional to the KD (29).
Adding BFA to the cell surface stability assay allows us to
measure the amount of time a peptide-MHC complex stays on
the surface of cells. As can be seen in Fig. 1C, the GP2 peptide
has an extremely short half-life of ;21 min at 37 °C (Table I).
Some of the other HER-2/neu-derived peptides have longer
half-lives, but none are as long as peptides such as ML or RT
(Fig. 1C and Table I). We could not detect binding of the E74
peptide in any of our assays. The fact that CTL activity toward
E74 can be seen and we cannot measure binding is probably a
function of the extreme sensitivity of CTL. Only ;100 class
I-peptide complexes/cell are required to trigger an activated T
cell (32).
Anchor Substitutions Do Not Significantly Improve Binding
of GP2—Substitutions at peptide anchor positions have been
shown to greatly increase the thermal stability of an influenza
matrix peptide (12). In the present work, we chose one of the
three poor binding peptides, GP2, to study the anchor substi-
tutions of HER-2/neu-derived peptides. The GP2 anchors (Ile at
position 2 and Leu at position 9 of the peptide) are found in
peptides that bind with high affinity to A2, but these anchors
are not optimal (8). Therefore, optimized APL based on GP2
were synthesized that replaced the Ile at position 2 with Leu
(I2L) or the Leu at position 9 with Val (L9V). As can be seen in
Fig. 1D, these substitutions did increase the thermal stability
(;2–6 °C) but not to the degree that was seen for similar
substitutions in the influenza matrix peptide (;7–9 °C) (12) or
for a variant of a melanoma peptide (MelA and MelA-A2L,
;9 °C). The cell surface stability assay using T2 cells supports
the CD data that we have measured (Fig. 1E). The half-lives of
the APL complexes on the cell surface are increased with re-
spect to GP2 (Fig. 1F). However, they are not close to the time
constants seen for the positive control, high affinity binders ML
or RT.
Crystallographic Structure of A2-GP2—To understand why
GP2 binds poorly to A2 and why the anchor substitutions do
not significantly increase the stability, we determined the crys-
tallographic structure of A2-GP2. The molecular replacement
solution was unambiguous with a correlation coefficient of
;73% after rigid body fitting. The model was refined in X-
PLOR (33). During refinement, the peptide was omitted to
reduce the potential for model bias. Density modification was
performed with DM (22) using the X-PLOR output coordinates
to generate unbiased averaged electron density maps of the
peptide and to fit the structure of A2. Unlike all of the pMHC
structures that we have determined to date, the entire length of
the main chain of the peptide was not visible in the density
modified electron density maps at this stage. After 10 cycles of
model building with O (27) and computational refinement with
X-PLOR and Refmac and finally with CNS, the refinement
converged to the statistics shown in Table II. In general, the
maps are clear and unambiguous. The entire A2 molecule is
well resolved and fits the density well as evidenced by an
average real space correlation coefficient of 83.8%. The posi-
tions of the termini of the GP2 peptide are also unambiguous
and never altered through the course of refinement. However,
unlike all reported pMHC structures, the center of the peptide
never became clear in the density (Fig. 2). In addition, standard
2Fo 2 Fc maps, simulated annealing omit maps, unaveraged
omit maps, and composite omit maps failed to show density for
the center of the peptide. In particular, the orientation of res-
idue 6 (Val) is completely uninterpretable, and the positions of
residues 5 and 7 (Val and Gly, respectively) are not well
defined.
DISCUSSION
One hypothesis used to explain why tumors are not recog-
nized and eliminated by the immune system is that potentially
TABLE II
Summary of crystallographic data
The crystallographic structure of A2-GP2 was determined by molec-
ular replacement using the A2-hepatitis B 10-mer (Protein Data Bank
code 1HHH) as the search model. The structure was refined by a
combination of X-PLOR and Refmac. Individual Bs were refined in the
penultimate cycle followed by the addition of waters.
Data statistics
Space group P1
Cell Dimensions a 5 50.34 Å
b 5 63.61 Å
c 5 75.14 Å
a 5 81.98 °
b 5 76.25 °








Completeness (%) 98.2 (97.6)
Refinement
Resolution 30–2.4 Å
Rfree (%) (number of reflections)
c 28.4 (1,714)
Rwork (%) (number of reflections)
c 24.2 (31,969)
Rs fitd 83.8%
No. of non-hydrogen atoms 6,292
No. of waters 103
Errore 0.26 Å
Average B factor 16.8 Å2
R.M.S. deviations from ideality
Bonds 0.009 Å
Angles 1.468 °





a Rmerge 5 Shkl SiuIi 2 ,I.u/Shkl SiIi, where Ii is the observed intensity
and ,I. is the average intensity of multiple observations of symmetry
related reflections.
b Number in parenthesis refers to the highest resolution shell (2.44–
2.40) for A2-GP2 unless otherwise stated.
c R 5 Shklu uFobsu 2 k uFcalu u/Shkl uFobsu, where Rfree is calculated for a
randomly chosen 5% of reflections and Rwork is calculated for the re-
maining 95% of reflections used for structure refinement.
d Rs fit is the average real space fit of all atoms on an electron density
map from DM with 2-fold noncrystallographic averaging, histogram
matching, and solvent flattening.
e Error is the mean estimate of the coordinate error based on maxi-
mum likelihood methods (Refmac).
The Center of GP2 Is Flexible when Bound to HLA-A236424
immunologically reactive peptides do not bind well to class I
MHC molecules. If the peptides dissociate from class I MHC
molecules too quickly, the cells presenting the peptides do not
have a sufficient concentration of the specific pMHC at the sur-
face of the cell to be recognized by circulating T cells. We exam-
ined binding of a selection of known immunologically recognized
FIG. 1. HER-2/neu-derived peptides bind poorly to A2, and anchor substitutions do not increase the stability of GP2-derived APL.
The symbols and colors shown in A are also those used in B and C. Likewise, the symbols and colors shown in D are also those used in E and F.
A, thermal stability of A2-peptide complexes as measured by CD. 4–12 mM protein was denatured by heat in a circular dichroism spectropola-
rimeter. The change in CD signal at 218 nm is an indication of the loss of secondary structure within the protein. Each curve is the average of three
independent experiments. The error in the Tm is the sum of the curve fit error and the Peltier temperature controller error and is ;1 °C. B, cell
surface measurements confirm relative affinities measured by circular dichroism. T2 cells were incubated with the indicated concentrations of
peptide and the amount of cell surface A2 measured by flow cytometry using an A2-specific monoclonal antibody BB7.2. C, cell surface half-lives
of A2-peptide complexes were determined by treating the peptide-pulsed cells (as in B) with BFA to halt vesicular transport. Aliquots of cells were
removed at the indicated times and the remaining A2 on the cells determined by incubating with BB7.2. D, CD experiments show that anchor
substitutions of GP2 do not greatly increase the stability. The best peptide is the double substitution I2L/L9V, but even it is deficient compared
with ML. E, T2 cell surface stabilization confirms the CD data. F, the cell surface half-lives are moderately increased compared with GP2.
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peptide ligands from the tyrosine kinase family member HER-2/
neu. Despite the presence of CTL that recognize these peptides
bound to A2, the tumors are not eliminated. These HER-2/neu
peptides displayed a spectrum of binding affinities, but all were
lower than the level observed for high affinity binders, such as
ML or RT. Of particular interest to the immunology of tumor
recognition was the clustering of many of these peptides in the
“low affinity” category. Remarkably, all of these peptides, (GP2,
C84, and F56) have good anchor residues for A2.
There are two primary reasons to examine this phenomena
in detail. The first is to understand how class I MHC binds
peptides. There is a great deal known about how class I MHC
binds many peptides with great sequence diversity, but there is
very little information about how the protein binds any partic-
ular peptide well or poorly. There are now many examples of
crystal structures of high affinity peptides bound to class I
MHC. GP2 is a perfect example of a poor binding peptide and as
such offers the first opportunity to understand poor binding.
The second reason to examine GP2 is that poor affinity pep-
tides are potentially better targets for immunotherapy. The
rationale for this has to do with T cell education. T cells are
selected for survival by two mechanisms (positive and negative
selection) in the thymus (35). If a self-peptide binds to class I
MHC with high affinity, there is a larger concentration of
pMHC in the thymus and thus a greater chance that T cells
would be able to recognize the complex well. Presumably, this
set of T cells would be deleted from the T cell receptor reper-
toire, and they would not be in the periphery. If the self-peptide
binds with poor affinity, the concentration of that peptide-MHC
molecule in the thymus may be too low for recognition during
the selection process. Therefore, there is a greater probability
of finding these T cells in the periphery.
A complex of A2 with GP2 bound has poor thermal stability
(Tm, 36.4 °C) and a very short cell surface half-life (;21 min).
Many laboratories including ours have improved the binding
affinity of peptides by changing the anchor residues to those
most preferred by A2 (13, 36). As an example, we show that a
small change in the anchor position of the melanoma peptide
MelA results in a peptide with much greater binding affinity.
However, trials with substitutions of GP2 at the anchor posi-
tions showed that the affinity was not significantly improved
(Table I). Our goal is to be able to design APL for cancer
immunotherapy. To be able to do this in a reasonable fashion,
we needed to determine the crystallographic structure of A2-
GP2 and determine why this peptide binds poorly.
The crystallographic structure shows uninterpretable elec-
tron density within the center of the peptide. Our interpreta-
tion of these data is that the peptide does not assume one
unique conformation in the center as has been seen for all other
single peptide-MHC structures to date (reviewed in Ref. 4).
Interestingly, this is analogous to the situation found in the
crystal structure of a class I MHC complex that contained a
mixture of many different peptides (37). These data suggest
that anchor substitutions do not significantly increase the af-
finity of GP2 because they do not address the fundamental
problem that the peptide has in binding. The center does not
make stabilizing contacts with the binding cleft of the class I
MHC molecule.
This result begs another important immunological question.
Does the flexibility in the center of the peptide increase or
decrease immunogenicity? On the one hand, the flexibility de-
creases the already small concentration of a specific molecular
surface that can interact with the T cell receptor on a circulat-
ing T cell. On the other hand, multiple peptide conformations
generate more molecular surfaces that can be potentially rec-
ognized by circulating T cells. Perhaps in the context of a
peptide that binds well, increased flexibility is more immuno-
genic, but in the context of a poor binding peptide increased
flexibility does not increase immunogenicity because of the
reduced concentration effect.
There is increasing interest in using peptides that bind to
class I MHC for immunotherapy. As is the case of vaccination
used to prevent viral infection, the potential therapeutic value
is significant. As more antigens are discovered that are recog-
nized by CTL and yet bind poorly to class I MHC molecules, the
rules that predict binding affinity will be more critical. The
phenomena observed here for GP2 certainly applies to other
poor binding peptides whose binding affinity is not increased by
altering the anchor residues. Increased affinity can be obtained
for many of these peptides, but a full understanding of how
peptides bind to class I MHC is still needed. By examining the
binding of GP2 at the atomic level, we have made another step
toward understanding peptide binding well enough to make
predictions that will increase peptide affinity and minimize
immunological consequences.
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